All Stories

  1. Prognostic Significance of the CPS-EG Score in Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy

    Article • Cancers, July 2026, MDPI AG

    İsmail Beypinar

  2. Evaluation of the predictive and prognostic performance of the PILE score in metastatic renal cell carcinoma

    Article • Frontiers in Medicine, July 2026, Frontiers

    İsmail Beypinar

  3. Real-World Treatment Outcomes After Nivolumab Progression in BRAF-Negative Metastatic Melanoma: A Multicenter Cohort Study by the Turkish Oncology Group

    Article • Journal of Clinical Medicine, July 2026, MDPI AG

    İsmail Beypinar

  4. Safety Profile Comparison of Androgen Receptor Pathway Inhibitors: A Pharmacovigilance Signal Detection Analysis Using Disproportionality Methods and Age-Stratified Comparison of 37,875 FAERS Reports

    Article • Clinical Genitourinary Cancer, July 2026, Elsevier

    İsmail Beypinar

  5. Immunosuppressive Tumor Microenvironment Signatures Predict Early Progression in NSCLC Patients Receiving Immune Checkpoint Inhibitors: A Transcriptomic and Immune Deconvolution Analysis of GSE135222

    Article • Medicina, May 2026, MDPI AG

    İsmail Beypinar

  6. Does the Duration of FLOT Infusion Change the Outcome of Perioperative Treatment for Gastric Cancer? Comparing 24- and 48-h Infusions

    Article • Medicina, May 2026, MDPI AG

    İsmail Beypinar

  7. Psoas muscle indices, visceral fat distribution, inflammatory markers and 90-day mortality in palliative medicine: retrospective cohort study

    Article • BMJ Supportive & Palliative Care, May 2026, BMJ

    İsmail Beypinar

  8. Modified albumin-bilirubin grade predicts overall and progression-free survival in metastatic gastric cancer

    Article • Biomolecules and Biomedicine, May 2026, Association of Basic Medical Sciences of FBIH

    İsmail Beypinar

  9. Bone Metastasis Distribution Matters: Prognostic Effect of the Axial‐to‐Peripheral Ratio in Metastatic Hormone‐Sensitive Prostate Cancer

    Article • The Prostate, April 2026, Wiley

    İsmail Beypinar

  10. Immune Checkpoint Inhibitors and Bone Health: Mechanisms, Clinical Implications, and Emerging Perspectives on Bone Fragility

    Article • Current Osteoporosis Reports, March 2026, Springer Science + Business Media

    İsmail Beypinar

  11. Prevalence and Reactivation of Hepatitis B and C in Patients Undergoing Chemotherapy for Solid Tumors

    Article • JCO Global Oncology, March 2026, American Society of Clinical Oncology (ASCO)

    İsmail Beypinar

  12. Evaluation of Inflammatory Parameters and Ferritin as Prognostic Factors in Non-small Cell Lung Cancer Patients Receiving Nivolumab Immunotherapy

    Article • Biomarkers, January 2026, Taylor & Francis

    İsmail Beypinar

  13. THE EXPRESSION AND PROGNOSTIC SIGNIFICANCE OF IDH1-R132H MUTATION IN ENDOMETRIAL CARCINOMA

    Article • Kocatepe Tıp Dergisi, January 2026, Kocatepe Medical Journal

    İsmail Beypinar

  14. Long-Term Oncological Outcomes for Locally Advanced Rectal Cancer Patients with Pathological Complete Response After Neoadjuvant Chemoradiotherapy: A Turkish Oncology Group Study

    Article • Cancer Investigation, December 2025, Taylor & Francis

    İsmail Beypinar

  15. Prognostic Effect of KELIM Score of Prostate‐Specific Antigen in Hormone‐Sensitive Prostate Cancer Patients Treated With Novel Androgen Receptor Inhibitors: Pioneering New Ways

    Article • The Prostate, November 2025, Wiley

    İsmail Beypinar

  16. 406P Risk of second primary cancer in a ten-year follow-up period among turkish breast cancer survivors: Results from the turkish oncology group cohort

    Article • Annals of Oncology, September 2025, Elsevier

    İsmail Beypinar

  17. Comparison of the efficacy of mFOLFOX-6 and mDCF regimens in the treatment of metastatic gastric cancer: a multicenter retrospective study

    Article • Therapeutic Advances in Medical Oncology, August 2025, SAGE Publications

    İsmail Beypinar

  18. LOCALIZE SCROTAL KAPOSI SARCOMA IN A HIV-NEGATIVE PATIENT

    Article • Kocatepe Tıp Dergisi, July 2025, Kocatepe Medical Journal

    İsmail Beypinar

  19. Novel tumor marker index combining carcinoembryonic antigen and carbohydrate antigen 19-9: New prognostic factor for metastatic colorectal cancer

    Article • World Journal of Gastrointestinal Oncology, May 2025, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    İsmail Beypinar

  20. Real-life data on adjuvant trastuzumab emtansine treatment in early-stage HER2-positive breast cancer: a Turkish Oncology Group study

    Article • Anti-Cancer Drugs, April 2025, Wolters Kluwer Health

    İsmail Beypinar

  21. Author Correction: The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study

    Article • Scientific Reports, March 2025, Springer Science + Business Media

    İsmail Beypinar

  22. Prognostic value of IMDC score in non-small cell lung cancer receiving immunotherapy: old dog, new tricks?

    Article • European Journal of Clinical Pharmacology, February 2025, Springer Science + Business Media

    İsmail Beypinar

  23. Inflammatory Biomarkers from Blood Counts as Prognostic Tools in Metastatic Esophageal Cancer

    Article • Medical Science Monitor, January 2025, International Scientific Literature

    İsmail Beypinar

  24. Are they all the same? Different effects of opioid types on survival in metastatic NSCLC receiving nivolumab

    Article • American Journal of Cancer Research, January 2025, e-Century Publishing Corporation

    İsmail Beypinar

  25. The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study

    Article • Scientific Reports, October 2024, Springer Science + Business Media

    İsmail Beypinar

  26. Comparison of granisetron and palonosetron in triplet anti-emetic prophylaxis in non-small cell lung cancer patients receiving cisplatin-based highly emetogenic chemotherapy

    Article • Journal of Oncology Pharmacy Practice, August 2024, SAGE Publications

    İsmail Beypinar

  27. Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG study

    Article • Breast Cancer Research and Treatment, August 2024, Springer Science + Business Media

    İsmail Beypinar

  28. BEFORE & AFTER: THE EVALUATION OF THE EFFECT OF THE COVID-19 PANDEMIC ON CANCER PATIENTS IN PALLIATIVE CARE CENTER

    Article • Kocatepe Tıp Dergisi, July 2024, Kocatepe Medical Journal

    İsmail Beypinar

  29. Adrenocortical Cancer in the Real World: A Comprehensive Analysis of Clinical Features and Management from the Turkish Oncology Group (TOG)

    Article • Clinical Genitourinary Cancer, June 2024, Elsevier

    İsmail Beypinar

  30. The Utility of the Cachexia Index and the Modified Glasgow Score in Young Patients With Breast Cancer

    Article • Cureus, April 2024, Springer Science + Business Media

    İsmail Beypinar

  31. Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study

    Article • Journal of Chemotherapy, March 2024, Taylor & Francis

    İsmail Beypinar

  32. Cancer Care After the Earthquake? What Is Left to Us?

    Article • JCO Clinical Cancer Informatics, March 2024, American Society of Clinical Oncology (ASCO)

    İsmail Beypinar

  33. The correlation between pre-treatment CEA levels and the EGFR mutation status in advanced lung adenocarcinoma

    Article • Journal of Cancer Research and Therapeutics, January 2024, Medknow

    İsmail Beypinar

  34. After an Earthquake: The Comparison of Psychological Status of Resident and Earthquake Survivor Cancer Patients

    Article • Disaster Medicine and Public Health Preparedness, January 2024, Cambridge University Press

    İsmail Beypinar

  35. Laboratory Parameters Predicting Brain Metastasis in Patients with Lung Cancer

    Article • Turkish Journal of Oncology, January 2024, LookUs Bilisim, Ltd.

    İsmail Beypinar

  36. The efficacy of IMDC score in Malignant Melanoma

    Article • Cancer Biomarkers, November 2023, IOS Press

    İsmail Beypinar

  37. Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, August 2023, New England Journal of Medicine (NEJM/MMS)

    İsmail Beypinar

  38. Kanser hastalarında aşılanma durumu ve aşılanmayı etkileyen faktörlerin değerlendirilmesi

    Article • Acta Medica Alanya, December 2022, Acta Medica Alanya

    İsmail Beypinar

  39. Three Perspectives: The Approach of Neoadjuvant Treatment of Rectum Cancer According to Medical Oncologists, Radiation Oncologists, and Surgeons

    Article • January 2022, Research Square

    İsmail Beypinar

  40. A New Prognostic Index in Young Breast Cancer Patients

    Article • Journal of College of Physicians And Surgeons Pakistan, January 2022, College of Physicians and Surgeons Pakistan

    İsmail Beypinar

  41. Microsatellite instability (MSI) in endometrial cancer; frequency and prognostic significance

    Article • The Annals of Clinical and Analytical Medicine, January 2022, Journal of Clinical and Analytical Medicine

    İsmail Beypinar

  42. The Effect of COVID-19 on Radiation Oncology Practice in Türkiye

    Article • Turkish Journal of Oncology, January 2022, LookUs Bilisim, Ltd.

    İsmail Beypinar

  43. Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study

    Article • Cancer Investigation, December 2021, Taylor & Francis

    İsmail Beypinar

  44. The Effect of The Body Composition to Prognosis in Young Breast Cancer Patients

    Article • Akdeniz Medical Journal, September 2021, Akdeniz University

    İsmail Beypinar

  45. Prognostic Value of Systemic Immune Index in Patients with Metastatic Gastric Cancer

    Article • European Archives of Medical Research, June 2021, Journal of Clinical Research of Pediatric Endocrinology

    İsmail Beypinar

  46. Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience

    Article • Cancer Investigation, June 2021, Taylor & Francis

    İsmail Beypinar

  47. The effect of body composition on prognosis in critically ill COVID-19 patients

    Article • The Annals of Clinical and Analytical Medicine, June 2021, Journal of Clinical and Analytical Medicine

    İsmail Beypinar

  48. Investigation of the Effect of Tumor Location in Patients with Stage III Colon Cancer Receiving Adjuvant Oxaliplatine-Based Adjuvant Chemotherapy

    Article • International Journal of Hematology and Oncology, March 2021, Akademi Doktorlar Yayinevi

    İsmail Beypinar

  49. The View of Turkish Oncologists Regarding MSI Status and Tumor Localization in Stage II and III Colon Cancer

    Article • Journal of Gastrointestinal Cancer, November 2020, Springer Science + Business Media

    İsmail Beypinar, Prof Dr Faruk Nuri Aykan

  50. GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients

    Article • Lung Cancer, October 2020, Elsevier

    İsmail Beypinar

  51. Intravenous Chemotherapy Adherence of Cancer Patients in Time of Covid-19 Crisis

    Article • International Journal of Hematology and Oncology, September 2020, Akademi Doktorlar Yayinevi

    İsmail Beypinar

  52. The Real-Life Data of BRAF Mutation on the Treatment of Colorectal Cancer: a TOG Study

    Article • Journal of Gastrointestinal Cancer, September 2020, Springer Science + Business Media

    Assoc. Prof. Yakup Ergun, İsmail Beypinar

  53. Adjuvant chemotherapy in gastric cancer

    Article • Journal of Cancer Prevention & Current Research, June 2020, MedCrave Group LLC

    İsmail Beypinar

  54. The Effect of The Body Composition to Prognosis in Young Breast Cancer Patients

    Article • June 2020, Research Square

    İsmail Beypinar

  55. Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial

    Article • Balkan Medical Journal, February 2020, AVES Publishing Co.

    İsmail Beypinar

  56. The Comparison of Central Venous Port Catheters in Gastrointestinal Cancer Treatment

    Article • Journal of Oncological Sciences, January 2020, Journal of Oncological Sciences (JOS)

    İsmail Beypinar

  57. The Effect of the Prognostic Nutritional Index on Chemoradiotherapy Response in Lung Cancer

    Article • Journal of Oncological Sciences, January 2020, Journal of Oncological Sciences (JOS)

    İsmail Beypinar

  58. P1.14-15 Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey

    Article • Journal of Thoracic Oncology, October 2019, Elsevier

    İsmail Beypinar

  59. The compliance with antiemetic guidelines of Turkish medical oncologists. A survey study of Turkish Oncology Group

    Article • Current Problems in Cancer, August 2019, Elsevier

    İsmail Beypinar

  60. Comparison of palonosetron and granisetron in triplet antiemetic therapy in nonmetastatic breast cancer patients receiving high emetogenic chemotherapy: a multicenter, prospective, and observational study

    Article • Cancer Chemotherapy and Pharmacology, April 2019, Springer Science + Business Media

    İsmail Beypinar

  61. Are preoperative serum CA15-3 levels different in breast cancer subgroups?

    Article • Current Problems in Cancer, April 2019, Elsevier

    İsmail Beypinar

  62. Does Vitamin D Replacement Alter the Chemotherapy Outcome in Lung Cancer

    Article • Eurasian Journal of Medicine and Oncology, January 2019, Kare Publishing

    İsmail Beypinar

  63. Is TTF-1 a prognostic marker in non-small cell lung adenokarsinoma?

    Article • Medicine Science | International Medical Journal, January 2019, ScopeMed International Medical Journal Management and Indexing System

    İsmail Beypinar

  64. Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes

    Article • Cancer Chemotherapy and Pharmacology, October 2018, Springer Science + Business Media

    İsmail Beypinar

  65. Comparison of palonosetron and granisetron in triplet antiemetic therapy in nonmetastatic breast cancer patients receiving high emetogenic chemotherapy. A multicenter, prospective, and observational study

    Article • Annals of Oncology, October 2018, Elsevier

    İsmail Beypinar

  66. Efficiency and safety of regorafenib in metastatic colorectal cancer (mCRC): Real life experience from Turkey.

    Article • Journal of Clinical Oncology, May 2018, American Society of Clinical Oncology (ASCO)

    İsmail Beypinar

  67. Cetuximab Treatment for Head and Neck Skin Cancer in a Patient with Heart Transplantation

    Article • Turkiye Klinikleri Cardiovascular Sciences, January 2018, Ortadogu Reklam Tanitim Yayincilik Turizm Egitim Insaat Sanayi ve Ticaret A.S.

    İsmail Beypinar

  68. The Relationship Between the Level of Parathormone and the Existence and the Degree of Coronary Atherosclerosis

    Article • Turkish Journal of Endocrinology and Metabolism, January 2018, AVES Publishing Co.

    İsmail Beypinar

  69. Oxaliplatin induced acute immune-mediated thrombocytopenia; a case report

    Article • Journal of Oncological Sciences, April 2017, Journal of Oncological Sciences (JOS)

    İsmail Beypinar